Form D · Biotechnology

Avenzo Therapeutics, Inc.

San Diego, CA · CIK 0001947742

Offering snapshot reported Sep 5, 2025 · SEC filing

Reported sold
$47.2M
Offering amount: $75M
Investors reported
20
Form D · investor count
Minimum accepted
Not reported
Reported outside-investor minimum
First sale
Aug 22, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 5, 2025Initial$47,230,787No comparison20SEC filing
Nov 20, 2024Amendment$385,850,004$162,500,002vs Mar 26, 202422SEC filing
Mar 26, 2024Amendment$223,350,002$191,850,003vs Sep 29, 202219SEC filing
Sep 29, 2022Initial$31,499,999No comparison6SEC filing

Offering details

Securities
Not reported
Exemptions
Not reported
Duration over one year
Not reported
Business combination
Not reported
Sales commissions
$0
Finders' fees
$0
Form D file number
021-556725

Source: Form D, filed Sep 5, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Athena Countouriotis Director, Executive
Jakob Dupont, M.D., M.A. Director
Simeon George Director
Carl Gordon Director
Mohammad Hirmand Executive
Judith Li Director
Scott Lipman Executive
Patrick Machado Director
Garry Nicholson Director
Michael Rome Director
Brian Sun Executive
Paolo Tombesi Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
12707 High Bluff Drive, Suite 200
San Diego, CA, 92130